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Defective Mitochondrial mRNA Maturation
Is Associated with Spastic Ataxia
Andrew H. Crosby,1,7,* Heema Patel,1,7 Barry A. Chioza,1 Christos Proukakis,1,2 Kay Gurtz,3
Michael A. Patton,1 Reza Sharifi,1 Gaurav Harlalka,1 Michael A. Simpson,1 Katherine Dick,1
Johanna A. Reed,1 Ali Al-Memar,4 Zofia M.A. Chrzanowska-Lightowlers,5 Harold E. Cross,6
and Robert N. Lightowlers5
In human mitochondria, polyadenylation of mRNA, undertaken by the nuclear-encoded mitochondrial poly(A) RNA polymerase, is
essential for maintaining mitochondrial gene expression. Our molecular investigation of an autosomal-recessive spastic ataxia with
optic atrophy, present among the Old Order Amish, identified a mutation of MTPAP associated with the disease phenotype. When
subjected to poly(A) tail-length assays, mitochondrial mRNAs from affected individuals were shown to have severely truncated poly(A)
tails. Although defective mitochondrial DNA maintenance underlies a well-described group of clinical disorders, our findings reveal a
defect of mitochondrial mRNAmaturation associated with human disease and imply that this disease mechanism should be considered
in other complex neurodegenerative disorders.In the current study, we investigated an extensive Old
Order Amish family in which multiple children were
affected by a slowly progressive autosomal-recessive
neurodegenerative condition, the key features of which
are cerebellar ataxia (limb and truncal), spastic paraparesis
(increased lower limb tone with brisk knee jerks and
extensor plantars, but no weakness), dysarthria (mixture
of cerebellar and spastic), optic atrophy, learning difficul-
ties, and, in some, emotional liability. The clinical features
found in the affected individuals are shown in detail in
Table 1. Speech and walking are usually delayed and
abnormal from the onset. The two younger cases (IX-6
and IX-7) have predominantly cerebellar gait and speech
disturbance. In the four older cases (IX-2 to IX-5), tongue
movements are slow and spastic, jaw jerk is brisk, and
two have increased tone in the upper limbs. Their parents
report a clear progressive decline in function, although all
are still independently mobile with a spastic ataxic gait,
with no obvious intellectual deterioration, needing only
mild assistance for most self-care. The most severely ataxic
is IX-5, whose oromandibular coordination has become so
poor that, since the age of 16, she has had to use a straw for
drinking. In addition to the parents’ accounts, the relative
severity of the clinical picture in the older individuals
compared to the much younger IX-6 and IX-7 also
supports the impression that this is a progressive condi-
tion. Diminished or absent upper limb and ankle reflexes
in older cases, which were said to have been present in
pediatric assessments, suggest additional progressive lower
motor neuron involvement. Older individuals attended
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The Americaneducation), but special tuition was required from early
on. Individual IX-3 had a full IQ estimate at age 12 of
only 47 (verbal 61, performance 45). All patients live
with their parents, none are married, and older individuals
either attend a special workshop or help with basic house-
hold tasks.
Assuming that a founder mutation was responsible, we
undertook a genome-wide microarray scan with DNA ex-
tracted from blood samples of family members obtained
with informed consent and following approved institu-
tional review board protocols. The genome-wide screen
was performedwithAffymetrix 250K SNPNspI arrays (Gen-
eservice) by usingDNA from the four affected cases initially
available (IX-2, IX-3, IX-4, IX-5; Figure 1A). Homozygosity
analysis identified a single autozygous region of 6.5 Mb on
chromosome 10p11.23, delimited by markers rs1144522
and rs910967, likely to correspond to the disease locus; no
other notable regions of autozygosity were observed. Auto-
zygosity across this interval was corroborated by
microsatellite marker analysis, determined by PCR amplifi-
cation, and subsequent analysis by polyacrylamide gel elec-
trophoresis, visualized by silver staining via standardmeth-
odologies (Figure 1B). Multipoint LOD scores were
calculated across the microsatellite markers with Simwalk
version 2.91,1,2 revealing a LODmax score of 7.64, assuming
an autosomal-recessive mode of inheritance, complete
penetrance, and a disease gene frequency of 0.0001%. The
putative disease locus is predicted to contain 46 genes, of
which 7 are hypothetical and 15 are pseudogenes. While
screening the remaining 24 genes, a nonsynonymous
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Table 1. Summary of Clinical Features of Affected Cases
Patient IX-2 IX-3 IX-4 IX-5 IX-6 IX-7
Age when seen (years) 27 26 25 18 2 6
Age at which walked (months) 12 (tiptoed until age 3) 16 11 (with falls) 12 24 (abnormal) 18 (with falls)
Age at which talked (years) 3 2 1 >1 2 2
Speech normal at onset? N N Y N N N
Optic atrophy Y Y Y Y NK NK
Nystagmus N Y (horizontal) Y (vertical) N N N
Emotional liability Y N Y Y N Y
Dysarthria Y Y Y Y Y Y
Tone in upper limbs Increased Normal Increased Normal Normal Normal
Tone in lower limbs Increased Increased Increased Increased Normal Normal
Power in limbs Normal Normal Normal Normal Normal Normal
Reflexes: biceps þ þ   þþ þ
Reflexes: supinator þ þ   þþ þ
Reflexes: triceps þ þ   þþ þ
Reflexes: knee þþþ þþþ  þþþ þþþ þþþ
Reflexes: ankle     þþ þþ
Plantars Mute Extensor Extensor Extensor Extensor Extensor
Limb ataxia Y Y Y Y N N
Gait ataxia Y Y Y Y Y Y
The following abbreviations are used: Y, yes; N, no; NK, not known; reflexes: , absent; þ, diminished; þþ, normal; þþþ, pathologically brisk.mitochondrial poly(A) RNA polymerase gene MTPAP
(c.1432A>G; Figure 1C). The c.1432A>G variant in exon
9 of PAPD1 creates a BamHI restriction endonuclease
recognition site. Exon 9 PCR products generated from
control and patient samples were subsequently digested
with one unit of BamHI and were visualized on agarose
gels. This sequence variant cosegregated with the disease
phenotype and was not detected in 600 control chromo-
somes of unaffected individuals of European ancestry.
Analysis of 200 control chromosomes from unaffected
individuals from the same Ohio Amish community identi-
fied a single heterozygous carrier of the sequence variant,
which is not unexpected in this endogamous community,
in which founder mutations are commonly associated
with rare inherited diseases in multiple families.3–5 The
resultant predicted p.N478D substitution occurs within
an N-P-F-E sequence (Figure 1D) located within one of
the most highly conserved regions of the molecule in all
species examined.6
In order to confirm that the c.1432A>G alteration is
pathogenic and to determine its functional consequence,
we undertook mitochondrial poly(A) tail (MPAT) assays
of representative mitochondrial-encoded transcripts
(RNA14 and MTCO1 [MIM 516030]) of the Amish family
with the putative mutation. These assays allowed us to
visualize the heterogeneous poly(A) tails of the various
species generated by mitochondrial poly(A) RNA poly-656 The American Journal of Human Genetics 87, 655–660, Novembmerase (mtPAP). RNA (2.5 mg) was extracted from whole
blood (PAXgene Blood RNA kit, QIAGEN) according to
the manufacturer’s instructions. Linker primers7 were
ligated with NEB T4 RNA ligase. All subsequent steps
were exactly as described in Temperley et al.,7 including
primer sequences for RNA14 and anti-ligation primer. For
MTCO1, first-round PCR primer was 50-CATATTCATC
GGCGTAAATC-30 and labeled second-round PCR primer
was 50-CAACCCCATGGCCTCCA-30. PCR profiles were as
described.7
Gels were exposed to PhosphorImage screens and
ImageQuant 5.2 software used for visualization and densi-
tometric analyses. Relative fraction of oligoadenylated
species was calculated as oligo/(oligo þ poly) and pre-
sented as a percentage. Oligoadenylated species were
defined as>10 nt extension from the deadenylated species
and were measured against the size markers. For polyade-
nylated species, RNA14 was defined as 30–50 nt exten-
sions, and MTCO1 was defined as 29–50 nt extensions.
As shown in Figure 2, oligoadenylated species were present
in all samples, consistent with previous reports in which
mtPAP had been depleted by small interfering RNA treat-
ment.6,8 Polyadenylation in both carrier parents appeared
to be normal, but the MPAT assay revealed a profound
effect on polyadenylation associated with homozygosity
of the sequence variant in all affected cases. Whereas
the percentage of oligoadenylated (>10 nt) versuser 12, 2010
Figure 1. Identification of MTPAP Mutation in Amish Pedigree
(A) Pedigree diagram of Amish family.
(B) Marker genotypings across the region of homozygosity identified by whole-genome SNP analysis. Initial genome-wide screen was
undertaken in individuals IX-2, IX-3, IX-4, and IX-5 for which samples were available at the time. The region of autozygosity defined
was delimited by SNPs rs1144522 and rs910967. The mutation (NC_000010.10: g.30602855T>C; NM_018109.3: c.1432A>G) is shown
in red. All affected individuals, including IX-6 and IX-7, were subsequently found to be homozygous for the c.1432A>G variant, whereas
parental samples and the unaffected sibling were carriers.
(C) Electropherograms showing MTPAP exon 9 sequence encompassing the NM_018109.3: c.1432A>G variant in a wild-type (WT)
control, a heterozygous carrier parent, and a homozygous affected individual.
(D) ClustalW2 alignment of the region encompassing the PAP/25A-associated domain of MTPAP from various species. Amino acid
altered by the c.1432A>G substitution (p.N478D) is indicated with the red arrow.polyadenylated (>30 nt extension) RNA14 transcript was
less than 10% in the unaffected parent carriers (Figure 2,
bottom, lanes 1 and 2), a dramatic reversal in this ratio was
apparent in all patients homozygous for the c.1432A>G
mutation (87%–93%, lanes 3–6). A second transcript,
MTCO1, was also assessed (Figure 2, top), with similar
results (unaffected parents 23%–40%, affected siblings
80%–92%). Together with the genetic data, these findings
strongly suggest that the p.N478DmtPAP is responsible for
the condition in this family.
What is the function of polyadenylation in the mamma-
lian mitochondrion? The answer is complex and, to date,
has not been fully resolved. Terminal 30 oligoadenylation
of mitochondrial mRNAs is clearly essential, because pro-The Americancessing of several mitochondrial open reading frames
from the primary polycistronic transcript leaves a trun-
cated terminal codon that requires adenylation for com-
pletion.9 Polyadenylation of mRNA is, however, crucial
for maintaining global mRNA expression in mammalian
mitochondria.8,10,11 Depletion of mtPAP clearly causes
instability of some transcripts,8 but not others.6,10,11
Indeed, enzymatic removal of the poly(A) tail from mito-
chondrial transcripts in intact cells can actually promote
stability of a subset of mRNAs.11 In contrast, occlusion of
the poly(A) extensions clearly leads to a decrease in trans-
lation efficiency.11 Although the exact role or roles of mito-
chondrial mRNA polyadenylation remain unclear, deple-
tion of mtPAP has a profound effect on mitochondrialJournal of Human Genetics 87, 655–660, November 12, 2010 657
Figure 2. Poly(A) Status of Representative Mitochondrial mRNAs from Patient and Control Samples Available
RNA (2.5 mg) from each individual was ligated to linker and subjected to the mitochondrial poly(A) tail-length assay as described in
Temperley et al.7 Radiolabeled products were separated through a 10% denaturing polyacrylamide gel, and lengths were calculated
by comparison against size markers (P32 end-labeled synthetic oligomers of 20 and 75 nt). Oligoadenylated (<10 nt extension from
processed transcript) or polyadenylated (35–50 nt extension RNA14; 29–50 ntMTCO1) species were quantified following densitometric
scans (ImageQuant software). Lane 1 denotes the mother, lane 2 denotes the father, and lanes 3–6 denote the affected children. The
following abbreviations are used: H, HEK293T control cell line; C1 and C2, negative amplification controls from the first and second
rounds of PCR; M, size marker; F, control fibroblast cell line. Top: MTCO1 transcript; bottom: RNA14 transcript.
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function8 and is evidenced by the severe neurodegenera-
tive disorder found in this family.
Inherited mitochondrial disorders commonly affect
postmitotic tissues, such as muscle and the central and
peripheral nervous system, and are widely acknowledged
as an important cause of neurological disease, with cere-
bellar ataxia a frequent feature and occasionally the main
one (e.g., the mitochondrial recessive ataxia syndrome).
Adult-onset mitochondrial diseases are typically caused
by mutations within the mitochondrial genome, whereas
mutations in nuclear-encoded mitochondrial proteins
usually present with more severe childhood phenotypes
and multisystem disorders, in addition to neurological
involvement (reviewed in Rahman and Hanna12). These
childhood disorders are often associated with instability
of the mitochondrial genome, resulting in mtDNA dele-
tions (e.g., POLG [MIM 174763], POLG2 [MIM 604983],
ANT1 [MIM 103220], PEO1 [MIM 606075], OPA1 [MIM
605290], TYMP [MIM 131222]) or mtDNA depletion
(DGUOK [MIM 601465], SUCLA2 [MIM 603921], SUCLG1
[MIM 611224], RRM2B [MIM 604712], MPV17 [MIM
137960], TK2 [MIM 188250]).
In contrast, one category ofmitochondrial disorders that
is becoming increasingly diagnosed is that of nuclear gene
mutations that cause mitochondrial protein synthesis
disorders with no evidence of mtDNA involvement. This
highly heterogeneous group mostly shares a combined
disorder of respiratory chain complexes. To date, the
underlying genetic defects encode mt-tRNA modifying
and aminoacylating enzymes (PUS1, TRMU, DARS2,
RARS2, YARS2), an mRNA stability factor and translational
activator (LRPPRC, TACO1), translation factors (GFM1,
TUFM, TSFM, C12orf65), components of the mitochon-
drial ribosome (MRPS16/22), and factors that mediate
mitochondrial ribosome assembly (SPG7, AFG3L2). Clin-
ical presentations are diverse, but, other than the mt-
tRNAmodifying defects, almost all patients have neurolog-
ical deficits. Most strikingly, mutations in two components
of the mitochondrial mAAA protease that are essential for
mitochondrial ribosome maturation, paraplegin and
AFG3-like protein, cause hereditary spastic paraplegia
(SPG713) and cerebellar ataxia (SCA2814), respectively.
Both presentations are similar to the clinical disorder
that we have identified in patients with mtPAP defects.
The SPG7 phenotype can include cerebellar ataxia and
optic atrophy in addition to spastic paraparesis,15 and
SCA28 patients have pyramidal signs in addition to
ataxia.16 Similarly, Friedreich’s ataxia, the most common
autosomal-recessive ataxia, may display a comparable
phenotype to the patients described here with spasticity,
areflexia, and optic atrophy. Themutated protein, frataxin,
is also a mitochondrial protein, and the latest evidence
suggests that it is involved in synthesis of iron-sulfur
clusters whose diverse functions include electron transfer
in the mitochondrial respiratory complex.17 Although a
number of diverse molecular mechanisms lead to auto-
somal-recessive ataxias, our findings provide evidenceThe Americanof a new mitochondrial abnormality that may lead to a
complex neurodegenerative disorder with ataxia as the
prominent component.Acknowledgments
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